Science & Technology
Activating TFEB to enhance the efficacy of immunotherapy for triple negative breast cancer
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41CA298141-01
Award Ceiling
$400K
Award Floor
$400K
Close Date
Jan 31, 2026
Total Funding
$400K
Expected Awards
1
Posted Date
Feb 1, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R41CA298141-01
Description
STTR Phase Phase I award: "Activating TFEB to enhance the efficacy of immunotherapy for triple negative breast cancer" awarded to PROMILEAD, LLC in COLUMBIA, South Carolina. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $400,000. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.